On July 1, 2020, the National Academies of Sciences, Engineering, and Medicine (NASEM) published The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use,1 a report commissioned in September 2018. The US Food and Drug Administration (FDA) charged the NASEM to summarize the available evidence on compounded bioidentical hormone therapy (cBHT) and develop recommendations on the clinical utility of cBHT drug products, whether the current safety and effectiveness evidence supports use of these products to treat patients, and the patient populations that might require a cBHT drug product in place of an FDA-approved drug product.1
Stuenkel CA, Manson JE. Compounded Bioidentical Hormone Therapy: The National Academies Weigh In. JAMA Intern Med. 2021;181(3):370–371. doi:10.1001/jamainternmed.2020.7232
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.